A regimen of docetaxel and cisplatin offers better survival and response rates than a combination of vinorelbine and cisplatin in the treatment of advanced non-small-cell lung cancer, according to a phase 3 study published in the online version of the Journal of Clinical Oncology. In addition, the findings demonstrated that docetaxel is as effective as vinorelbine/cisplatin when combined with another platinum, carboplatin.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Docetaxel/platinum combinations are efficacious in treatment of NSCLC

Newsletter